Submissions from 2020
Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks., Helena Marzo-Ortega, Philip Mease, Proton Rahman, Victoria Navarro-Compán, Vibeke Strand, Maxime Dougados, Bernard Combe, James Cheng-Chung Wei, Xenofon Baraliakos, Theresa Hunter, David Sandoval, Xiaoqi Li, Baojin Zhu, Louis Bessette, and Atul Deodhar
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial., Iain B McInnes, Frank Behrens, Philip Mease, Arthur Kavanaugh, Christopher Ritchlin, Peter Nash, Jordi Gratacós Masmitja, Philippe Goupille, Tatiana Korotaeva, Alice B Gottlieb, Ruvie Martin, Kevin Ding, Pascale Pellet, Shephard Mpofu, and Luminita Pricop
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through 1 Year in Biologic-naïve Psoriatic Arthritis Patients., Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Soumya D Chakravarty, Xie L Xu, Ramanand A Subramanian, Prasheen Agarwal, Shihong Sheng, Yusang Jiang, Bei Zhou, Yanli Zhuang, Désirée van, der Heijde, and Philip Mease
Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management., Philip Mease
New treatments for PsA meet targeted therapy goals., Philip Mease
Preface to the psoriatic arthritis supplement., Philip Mease
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data., Philip Mease, Christina Charles-Schoeman, Stanley Cohen, Lara Fallon, John Woolcott, Huifeng Yun, Joel Kremer, Jeffrey Greenberg, Wendi Malley, Alina Onofrei, Keith S Kanik, Daniela Graham, Cunshan Wang, Carol Connell, Hernan Valdez, Manfred Hauben, Eric Hung, Ann Madsen, Thomas V Jones, and Jeffrey R Curtis
Reply to Letter to the Editor on Mease et al., Philip Mease, David H Collier, Gregory Kricorian, and James B Chung
Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study., Philip Mease, M Elaine Husni, Soumya D Chakravarty, Shelly Kafka, Dennis Parenti, Lilianne Kim, Kim Hung Lo, Elizabeth C Hsia, and Arthur Kavanaugh
Evaluation of changes in skin and joint outcomes and associated treatment changes in PsA: Experience from the Corrona PsA/SpA Registry., Philip Mease, Carol J Etzel, William Huster, April Armstrong, Talia Muram, Jeffrey Lisse, Sabrina Rebello, Rhiannon Dodge, Mwangi J Murage, Jeffrey D Greenberg, and William Malatestinic
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study., Philip Mease, Dafna D Gladman, Atul Deodhar, Dennis G McGonagle, Peter Nash, Wolf-Henning Boehncke, Alice Gottlieb, Xie L Xu, Stephen Xu, Elizabeth C Hsia, Chetan S Karyekar, and Philip S Helliwell
Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials., Philip Mease, Dafna D Gladman, Juan J Gomez-Reino, Stephen Hall, Arthur Kavanaugh, Eric Lespessailles, Georg Schett, Maria Paris, Nikolay Delev, Lichen Teng, and Jürgen Wollenhaupt
Treatment to Target in Psoriatic Arthritis with Apremilast: Probability of Achieving Targets and Comprehensive Control of Disease Manifestations., Philip Mease, Dafna D Gladman, Alexis Ogdie, Laura C Coates, Frank Behrens, Arthur Kavanaugh, Iain Mcinnes, Rubén Queiro, Benoit Guerette, Michele Brunori, Lichen Teng, and Josef S Smolen
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials., Philip Mease, Philip S Helliwell, Kasper Fjellhaugen Hjuler, Kyle Raymond, and Iain McInnes
Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial., Philip Mease, M Elaine Husni, Shelly Kafka, Soumya D Chakravarty, Diane D Harrison, Kim Hung Lo, Stephen Xu, Elizabeth C Hsia, and Arthur Kavanaugh
Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis., Philip J Mease, Iain B McInnes, Vibeke Strand, Oliver FitzGerald, Harris A Ahmad, Yedid Elbez, and Subhashis Banerjee
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study., Philip Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Juergen Rech, Stephen Hall, Piet Geusens, Pascale Pellet, Eumorphia Maria Delicha, Luminita Pricop, and Shephard Mpofu
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2., Philip Mease, Apinya Lertratanakul, Jaclyn K Anderson, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilova, Mauro Keiserman, Xin Wang, Sheng Zhong, Reva M McCaskill, Patrick Zueger, Aileen L Pangan, and William Tillett
Disease Characteristics, Quality of Life, and Work Productivity by Enthesitis Site: Real- World Data From the US Corrona Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Mei Liu, Sabrina Rebello, Winnie Hua, Robert R McLean, Peter Hur, and Alexis Ogdie
Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Mei Liu, Sabrina Rebello, Winnie Hua, Robert R McLean, Esther Yi, Yujin Park, and Alexis Ogdie
Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Mei Liu, Sabrina Rebello, Robert R McLean, Blessing Dube, Meghan Glynn, Peter Hur, and Alexis Ogdie
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial., Philip Mease, Proton Rahman, Alice B Gottlieb, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, Désirée van der Heijde, and Iain B McInnes
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial., Philip Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert, Paul Emery, Sreekumar G Pillai, and Philip S Helliwell
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study., Peter Nash, Laura C Coates, Alan J Kivitz, Philip Mease, Dafna D Gladman, José A Covarrubias-Cobos, Oliver FitzGerald, Dona Fleishaker, Cunshan Wang, Joseph Wu, Ming-Ann Hsu, Sujatha Menon, Lara Fallon, Ana Belén Romero, and Keith S Kanik
Measuring Outcomes in Psoriatic Arthritis., Alexis Ogdie, Laura C Coates, and Philip Mease
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis., Alexis Ogdie, Kurt de Vlam, Iain B McInnes, Philip J Mease, Philip Baer, Tatjana Lukic, David Gruben, Kenneth Kwok, Cunshan Wang, Ming-Ann Hsu, and Anna Maniccia
Measuring Outcomes in Axial Spondyloarthritis., Alexis Ogdie, Alí Duarte-García, Mark Hwang, Victoria Navarro-Compán, Désirée van der Heijde, and Philip Mease
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results., Alexis Ogdie, Mei Liu, Meghan Glynn, Kelechi Emeanuru, Leslie Harrold, Sven Richter, Benoit Guerette, and Philip Mease
Patient's experience of psoriatic arthritis: a conceptual model based on qualitative interviews., Alexis Ogdie, Kaleb Michaud, Miroslawa Nowak, Rachel Bruce, Sarah Cantor, Carlijn Hintzen, and Philip Mease
Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients., Ana-Maria Orbai, Iain B McInnes, Laura C Coates, M Elaine Husni, Dafna D Gladman, Laure Gossec, Luminita Pricop, Olivier Chambenoit, Xiangyi Meng, and Philip Mease
Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations., Shannon M Smith, Robert H Dworkin, Dennis C Turk, Michael McDermott, Christopher Eccleston, John T Farrar, Michael C Rowbotham, Zubin Bhangwagar, Laurie B Burke, Penney Cowan, Susan S Ellenberg, Scott R Evans, Roy L Freeman, Louis P Garrison, Smriti Iyengar, Alejandro Jadad, Mark P Jensen, Roderick Junor, Cornelia Kamp, Nathaniel P Katz, J Patrick Kesslak, Ernest A Kopecky, Dmitri Lissin, John D Markman, Philip Mease, Alec B O'Connor, Kushang V Patel, Srinivasa N Raja, Cristina Sampaio, David Schoenfeld, Jasvinder Singh, Ilona Steigerwald, Vibeke Strand, Leslie A Tive, Jeffrey Tobias, Ajay D Wasan, and Hilary D Wilson
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52., Josef S Smolen, Philip Mease, Hasan Tahir, Hendrik Schulze-Koops, Inmaculada de la Torre, Lingnan Li, Maja Hojnik, Christophe Sapin, Masato Okada, Roberto Caporali, Jordi Gratacós, Philippe Goupille, Soyi Liu Leage, Sreekumar Pillai, and Peter Nash
An interferon-gamma release assay as a novel biomarker in systemic lupus erythematosus., Jenna L Thomason, Uchechukwu M Obih, David M Koelle, Christian Lood, and And Grant Hughes
Outcomes of the 2019 GRAPPA Workshop on Continuous Composite Indices for the Assessment of Psoriatic Arthritis and Membership-recommended Next Steps., William Tillett, Neil McHugh, Ana-Maria Orbai, Alexis Ogdie, Ying Ying Leung, Laura C Coates, Philip Mease, Dafna D Gladman, Mel Brooke, Jon Packham, Denis O'Sullivan, Oliver FitzGerald, and Philip S Helliwell
Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research., Désirée van der Heijde, Dafna D Gladman, Arthur Kavanaugh, and Philip Mease
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5., Désirée van der Heijde, Philip Mease, Robert B M Landewé, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Xuan Zhu, Gregory Ligozio, Aimee Readie, Shephard Mpofu, and Luminita Pricop
Proceedings of the 2019 GRAPPA Collaborative Research Network Meeting., Robin Waxman, Carmel Stober, Deepak R Jadon, Ana-Maria Orbai, Vinod Chandran, Alexis Ogdie, Stephen R Pennington, Maarten de Wit, Denis O'Sullivan, Philip Mease, April W Armstrong, Kristina Callis Duffin, Philip S Helliwell, Leonieke J J van Mens, Christopher T Ritchlin, and Oliver FitzGerald
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019., Kevin L Winthrop, Michael E Weinblatt, Joan Bathon, Gerd R Burmester, Philip Mease, Leslie Crofford, Vivian Bykerk, Maxime Dougados, James Todd Rosenbaum, Xavier Mariette, Joachim Sieper, Fritz Melchers, Bruce N Cronstein, Ferry C Breedveld, Joachim Kalden, Josef S Smolen, and Daniel Furst
Submissions from 2019
Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population., Diana Brixner, Manish Mittal, David T Rubin, Philip Mease, Harry H Liu, Matthew Davis, Arijit Ganguli, and A Mark Fendrick
Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018., Alessandro Chiarotto, Ulrike Kaiser, Ernest Choy, Robin Christensen, Philip G Conaghan, Mary Cowern, Michael Gill, Maarten de Wit, Elizabeth Gargon, Ben Horgan, Jamie J Kirkham, Lee S Simon, Jasvinder A Singh, Peter Tugwell, Dennis C Turk, and Philip Mease
Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018., Alessandro Chiarotto, Ulrike Kaiser, Ernest Choy, Robin Christensen, Philip G Conaghan, Mary Cowern, Michael Gill, Maarten de Wit, Elizabeth Gargon, Ben Horgan, Jamie J Kirkham, Lee S Simon, Jasvinder A Singh, Peter Tugwell, Dennis C Turk, and Philip Mease
Measurement properties of the minimal disease activity criteria for psoriatic arthritis., Laura C Coates, Vibeke Strand, Hilary Wilson, Dennis Revicki, Brad Stolshek, Ahmed Samad, James B Chung, Dafna Gladman, and Philip Mease
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies., Laura C Coates, Johan K Wallman, Dennis McGonagle, Georg A Schett, Iain B McInnes, Philip Mease, Lawrence Rasouliyan, Erhard Quebe-Fehling, Darren L Asquith, Andreas E R Fasth, Luminita Pricop, and Corine Gaillez
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies., Laura C Coates, Johan K Wallman, Dennis McGonagle, Georg A Schett, Iain B McInnes, Philip Mease, Lawrence Rasouliyan, Erhard Quebe-Fehling, Darren L Asquith, Andreas E R Fasth, Luminita Pricop, and Corine Gaillez
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data., A Deodhar, Philip Mease, I B McInnes, X Baraliakos, K Reich, A Blauvelt, C Leonardi, B Porter, A Das Gupta, A Widmer, L Pricop, and T Fox
Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap., Atul Deodhar, Lianne S Gensler, Marina Magrey, Jessica A Walsh, Adam Winseck, Daniel Grant, and Philip Mease
Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 Psoriatic Arthritis workshop report., Alí Duarte-García, Ying Ying Leung, Laura C Coates, Dorcas Beaton, Robin Christensen, Ethan T Craig, Maarten de Wit, Lihi Eder, Lara Fallon, Oliver FitzGerald, Dafna D Gladman, Niti Goel, Richard Holland, Chris Lindsay, Lara Maxwell, Philip Mease, Ana Maria Orbai, Bev Shea, Vibeke Strand, Douglas J Veale, William Tillett, and Alexis Ogdie
GRAPPA 2018 Project Report., Niti Goel, Oliver FitzGerald, Dafna D Gladman, Philip S Helliwell, Arthur Kavanaugh, Walter P Maksymowych, Philip Mease, Christopher T Ritchlin, and Laura C Coates
Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients With Psoriatic Arthritis: A Prospective Cohort Study., Pil Højgaard, Karen Ellegaard, Sabrina Mai Nielsen, Robin Christensen, Jørgen Guldberg-Møller, Christine Ballegaard, Lene Dreyer, Philip Mease, Maarten de Wit, Lone Skov, Bente Glintborg, Henning Bliddal, Else Marie Bartels, Kirstine Amris, and Lars Erik Kristensen
Prevalence of Crystals in Knee Osteoarthritis: Experience From Patients Undergoing Arthroscopic Procedures., Robert Ike, Amrutha Baskaran, Jeannie Chao, Andrew L Concoff, Christopher W Wu, Bob Sun, Paul H Brion, Erin L Arnold, David J Klashman, John FitzGerald, and Kenneth C Kalunian
Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting., Deepak R Jadon, Vinod Chandran, Alexis Ogdie, Stephen R Pennington, Carmel Stober, Dafna D Gladman, Maarten de Wit, Denis O'Sullivan, Philip Mease, April W Armstrong, Kristina Callis Duffin, Conor Magee, Philip Helliwell, Christopher T Ritchlin, and Oliver FitzGerald
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis., Arthur Kavanaugh, Dafna D Gladman, Christopher J Edwards, Georg Schett, Benoit Guerette, Nikolay Delev, Lichen Teng, Maria Paris, and Philip Mease
The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set., Ying Ying Leung, Ana-Maria Orbai, Alexis Ogdie, Laura C Coates, Maarten de Wit, Kristina Callis Duffin, Lihi Eder, Dafna D Gladman, Niti Goel, Philip Mease, Vibeke Strand, Oliver FitzGerald, and William Tillett
Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a, Iain B McInnes, Gianfranco Ferraccioli, Maria-Antonietta D'Agostino, Manuela Le Bars, Subhashis Banerjee, Harris A Ahmad, Yedid Elbez, and Philip Mease
Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis., Philip Mease
Ustekinumab Fails to Show Efficacy in a Phase III Axial Spondyloarthritis Program: The Importance of Negative Results., Philip Mease
Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting., Philip Mease, Neil A Accortt, Sabrina Rebello, Carol J Etzel, Ryan W Harrison, Girish A Aras, Mahdi M F Gharaibeh, Jeffrey D Greenberg, and David H Collier
Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry., Philip Mease, Carol J Etzel, William J Huster, Talia M Muram, April W Armstrong, Jeffrey R Lisse, Sabrina Rebello, Rhiannon Dodge, Mwangi James Murage, Jeffrey D Greenberg, and William N Malatestinic
Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase 3 Trial., Philip Mease, Dafna D Gladman, David H Collier, Christopher T Ritchlin, Philip S Helliwell, Lyrica Liu, Gregory Kricorian, and James B Chung
Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry., Philip Mease, Chitra Karki, Mei Liu, YouFu Li, Bernice Gershenson, Hua Feng, Peter Hur, and Jeffrey D Greenberg
Axial Spondyloarthritis, Philip Mease and Muhammad Asim Khan
Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis in the United States: A Multicenter Observational Study., Philip Mease, Clive Liu, Evan Siegel, Heather Richmond, Meijing Wu, Liang Chen, Kevin Douglas, and Benjamin Lockshin
Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries., Philip Mease, Mei Liu, Sabrina Rebello, Hyungjoo Kang, Esther Yi, Yujin Park, and Jeffrey D Greenberg
Utilization of the validated Psoriasis Epidemiology Screening Tool (PEST) to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry., Philip Mease, J B Palmer, P Hur, B E Strober, M Lebwohl, C Karki, G W Reed, C J Etzel, J D Greenberg, and P S Helliwell
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial., Philip Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert, Paul Emery, Sreekumar G Pillai, and Philip S Helliwell
Biologic Treatment of Axial Spondyloarthritis, Philip Mease and F. Van den Bosch
Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis., Philip Mease, Jessica A Walsh, Xenofon Baraliakos, Robert Inman, Kurt de Vlam, James Cheng-Chung Wei, Theresa Hunter, Gaia Gallo, David Sandoval, Fangyi Zhao, Yan Dong, Rebecca Bolce, and Helena Marzo-Ortega
The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis., Philippe Mertz, Alexandre Belot, Ricard Cervera, Tyng Yu Chuah, Lorenzo Dagna, Laura Damian, Debashish Danda, David D'cruz, Gerard Espinosa, Camille Frances, David Jayne, Kong Kok Ooi, Eugene J Kucharz, Robert Lebovics, Isabelle Marie, Guillaume Moulis, Stanford Peng, Aman Sharma, Noboru Suzuki, Toshio Tanaka, Ronald Van Vollenhoven, Jean Sibilia, Jacques Eric Gottenberg, François Chasset, and Laurent Arnaud
Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor., Alexis Ogdie, J Lynn Palmer, Jeffrey Greenberg, Jeffrey R Curtis, Leslie R Harrold, Daniel H Solomon, Arthur Kavanaugh, Joel M Kremer, and Philip Mease
Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients., Ana-Maria Orbai, Iain B McInnes, Laura C Coates, M Elaine Husni, Dafna D Gladman, Laure Gossec, Luminita Pricop, Olivier Chambenoit, Xiangyi Meng, and Philip Mease
Measuring Psoriatic Arthritis Symptoms, A Core Domain in Psoriasis Clinical Trials., Lourdes Maria Perez-Chada, Alice Bendix Gottlieb, Jeffrey Cohen, Philip Mease, Kristina Callis Duffin, Amit Garg, John Latella, April Wang Armstrong, Alexis Ogdie, and Joseph Frank Merola
Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial., Thomas J Schnitzer, Richard Easton, Shirley Pang, Dennis J Levinson, Glenn Pixton, Lars Viktrup, Isabelle Davignon, Mark T Brown, Christine R West, and Kenneth M Verburg
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis., Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny, Jennifer Kwan-Morley, Janice Lin, Paula Marchetta, Philip Mease, Joseph F Merola, Julie Miner, Christopher T Ritchlin, Bernadette Siaton, Benjamin J Smith, Abby S Van Voorhees, Anna Helena Jonsson, Amit Aakash Shah, Nancy Sullivan, Marat Turgunbaev, Laura C Coates, Alice Gottlieb, Marina Magrey, W Benjamin Nowell, Ana-Maria Orbai, Soumya M Reddy, Jose U Scher, Evan Siegel, Michael Siegel, Jessica A Walsh, Amy S Turner, and James Reston
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis., Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny, Jennifer Kwan-Morley, Janice Lin, Paula Marchetta, Philip Mease, Joseph F Merola, Julie Miner, Christopher T Ritchlin, Bernadette Siaton, Benjamin J Smith, Abby S Van Voorhees, Anna Helena Jonsson, Amit Aakash Shah, Nancy Sullivan, Marat Turgunbaev, Laura C Coates, Alice Gottlieb, Marina Magrey, W Benjamin Nowell, Ana-Maria Orbai, Soumya M Reddy, Jose U Scher, Evan Siegel, Michael Siegel, Jessica A Walsh, Amy S Turner, and James Reston
Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study., Josef S Smolen, Dafna Gladman, H Patrick McNeil, Philip J Mease, Joachim Sieper, Maja Hojnik, Pascal Nurwakagari, and John Weinman
Consumer Prices for Surgical Management of Ankle Arthritis: Limited Availability and Wide Variability., Niall A Smyth, Brody J Dawkins, Joshua P Goldstein, Jonathan R Kaplan, Lew C Schon, and Amiethab A Aiyer
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond., Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Philip Mease, Dafna D Gladman, Linda Chen, Elizabeth Kudlacz, Joseph Wu, Joseph C Cappelleri, Thijs Hendrikx, and Ming-Ann Hsu
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs., Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, Philip Mease, Dafna D Gladman, Daniela Graham, Cunshan Wang, Joseph C Cappelleri, Thijs Hendrikx, and Ming-Ann Hsu
Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis., Vibeke Strand, Iain McInnes, Philip Mease, Peter Nash, Howard Thom, Chrysostomos Kalyvas, Matthias Hunger, Kunal Gandhi, Luminita Pricop, Steffen Jugl, and Ernest Choy
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5., Désirée van der Heijde, Philip Mease, Robert B M Landewé, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Xuan Zhu, Gregory Ligozio, Aimee Readie, Shephard Mpofu, and Luminita Pricop
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019., Kevin L Winthrop, Michael E Weinblatt, Joan Bathon, Gerd R Burmester, Philip Mease, Leslie Crofford, Vivian Bykerk, Maxime Dougados, James Todd Rosenbaum, Xavier Mariette, Joachim Sieper, Fritz Melchers, Bruce N Cronstein, Ferry C Breedveld, Joachim Kalden, Josef S Smolen, and Daniel Furst
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018., Kevin L Winthrop, Michael E Weinblatt, Mary K Crow, Gerd R Burmester, Philip Mease, Alexander K So, Vivian Bykerk, Ronald F Van Vollenhoven, Maxime Dougados, Jonathan Kay, Xavier Mariette, Joachim Sieper, Fritz Melchers, Bruce N Cronstein, Ethan Shevach, Ferdinand C Breedfeld, Joachim Kalden, Josef S Smolen, and Daniel E Furst
Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria., Frederick Wolfe, Stephen H Butler, MaryAnn Fitzcharles, Winfried Häuser, Robert L Katz, Philip Mease, Johannes J Rasker, Anthony S Russell, I Jon Russell, and Brian Walitt
Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria., Frederick Wolfe, Stephen H Butler, MaryAnn Fitzcharles, Winfried Häuser, Robert L Katz, Philip Mease, Johannes J Rasker, Anthony S Russell, I Jon Russell, and Brian Walitt
Submissions from 2018
Anti-Inflammatory Effects of Intra-Articular Hyaluronic Acid: A Systematic Review., Roy Altman, Asheesh Bedi, Ajay Manjoo, Faizan Niazi, Peter Shaw, and Philip Mease
Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study., Christine Ballegaard, Tanja S Jørgensen, Marie Skougaard, Vibeke Strand, Philip Mease, Lars E Kristensen, Lene Dreyer, Alice Gottlieb, Maarten de Wit, Robin Christensen, and Simon Tarp
Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study., Matthew A Brown, Paul A Bird, Philip C Robinson, Philip Mease, Filip van den Bosch, Christine Surian, Heather Jones, Annette Szumski, Lisa Marshall, Zirke Wiid, and Maxime Dougados
GRAPPA 2017 Project Report., Kristina Callis Duffin, Oliver FitzGerald, Artie Kavanaugh, Philip Mease, Joseph F Merola, Alexis Ogdie, Denis O'Sullivan, Soumya M Reddy, Christopher T Ritchlin, and Laura C Coates
Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study., Alberto Cauli, Dafna D Gladman, Alessandro Mathieu, Ignazio Olivieri, Giovanni Porru, Paul P Tak, Claudia Sardu, Raffaele Scarpa, Antonio Marchesoni, William J Taylor, Carlo Salvarani, Joachim Kalden, Ennio Lubrano, Sueli Carneiro, Matteo Piga, Alberto Floris, Francesca Desiati, John A Flynn, Salvatore D'Angelo, Arno W R van Kuijk, Maria Grazia Catanoso, Francesco Caso, Paolo Contu, Ilona Ujfalussy, Philip S Helliwell, and Philip Mease
Remission in psoriatic arthritis-where are we now?, Laura C Coates, Philip G Conaghan, Maria Antonietta D'Agostino, Maarten De Wit, Oliver FitzGerald, Tore K Kvien, Rik Lories, Philip Mease, Peter Nash, Georg Schett, Enrique R Soriano, and Paul Emery
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis., Laura C Coates, Oliver FitzGerald, Joseph F Merola, Josef Smolen, Leonieke J J van Mens, Heidi Bertheussen, Wolf-Henning Boehncke, Kristina Callis Duffin, Willemina Campbell, Maarten de Wit, Dafna Gladman, Alice Gottlieb, Jana James, Arthur Kavanaugh, Lars Erik Kristensen, Tore K Kvien, Thomas Luger, Neil McHugh, Philip Mease, Peter Nash, Alexis Ogdie, Cheryl F Rosen, Vibeke Strand, William Tillett, Douglas J Veale, and Philip S Helliwell
Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study., Laura C Coates, Philip Mease, Laure Gossec, Bruce Kirkham, Bintu Sherif, Corine Gaillez, Shephard Mpofu, Steffen M Jugl, Chetan Karyekar, and Kunal K Gandhi
Opioids vs Nonopioids for Chronic Back, Hip, or Knee Pain., Edward Covington, Charles Argoff, and Steven P Stanos
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis., Mark C Genovese, Michael E Weinblatt, Philip J Mease, Jacob A Aelion, Paul M Peloso, Kun Chen, Yihan Li, John Liu, Ahmed A Othman, Amit Khatri, Heikki T Mansikka, and Piotr Leszczynski
The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database., Dafna D Gladman, Laura C Coates, Deepak R Jadon, William Tillett, Philip Mease, and Marijn Vis
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies., Dafna D Gladman, Arthur Kavanaugh, Juan J Gómez-Reino, Jürgen Wollenhaupt, Maurizio Cutolo, Georg Schett, Eric Lespessailles, Benoit Guerette, Nikolay Delev, Lichen Teng, Christopher J Edwards, Charles A Birbara, and Philip J Mease
The Effect of Psoriatic Arthritis on Ixekizumab Clinical Outcomes in Moderate-to-Severe Psoriasis Patients: A Post Hoc Analysis., Alice B Gottlieb, Kim A Papp, Charles A Birbara, Catherine L Shuler, Russel Burge, Janelle Erickson, Lisa Kerr, and Philip J Mease
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)., Alice B Gottlieb, Vibeke Strand, Mitsumasa Kishimoto, Philip Mease, Diamant Thaçi, Julie Birt, Chin H Lee, Catherine L Shuler, Chen-Yen Lin, and Dafna D Gladman
Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: A prospective cohort study., Pil Højgaard, Karen Ellegaard, Sabrina Mai Nielsen, Robin Christensen, Jørgen Guldberg-Møller, Christine Ballegaard, Lene Dreyer, Philip Mease, Maarten de Wit, Lone Skov, Bente Glintborg, Henning Bliddal, Else Marie Bartels, Kirstine Amris, and Lars Erik Kristensen
A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative., Pil Højgaard, Louise Klokker, Ana-Maria Orbai, Kim Holmsted, Else M Bartels, Ying Ying Leung, Niti Goel, Maarten de Wit, Dafna D Gladman, Philip Mease, Lene Dreyer, Lars E Kristensen, Oliver FitzGerald, William Tillett, Laure Gossec, Philip Helliwell, Vibeke Strand, Alexis Ogdie, Caroline B Terwee, and Robin Christensen
